Personalized dendritic cell-based tumor immunotherapy

Immunotherapy

Volumn 2, Issue 1, 2010, Pages 57-68

  Janikashvili, Nona ^a   Laemonier, Nicolas ^a   Katsanis, Emmanuel ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer immune response; Chaperone protein; Dendritic cell idiotype; Personalized tumor vaccine; Tumor lysate

Indexed keywords

CANCER VACCINE; CHAPERONE; CHAPERONE RICH CELL LYSATE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VACCINATION;

ANIMALS; CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 77953391020     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.78     Document Type: Review

References (145)

1. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005).
2. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
3. Palucka AK, Ueno H, Fay J, Banchereau J: Dendritic cells: a critical player in cancer therapy? J. Immunother. 31, 793-805 (2008).
4. Gilboa E, Nair SK, LyerlyHK: Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol. Immunother. 46, 82-87 (1998).
5. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17, 163-169 (2005).
6. Palucka AK, Laupeze B, Aspord C et al.: Immunotherapy via dendritic cells. Adv. Exp. Med. Biol. 560, 105-114 (2005).
7. Mayordomo JI, ZorinaT, Storkus WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302 (1995).
8. Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf IG: Dendritic cells pulsed with oc-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int. Immunol. 18, 1279-1283 (2006).
9. Shimizu J, Suda T, Yoshioka T, Kosugi A, Fujiwara H, Hamaoka T: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142, 1053-1059 (1989).
10. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK: Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. 13, 439-447 (2003).
11. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
12. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 449, 419-426 (2007). ■ Highlights the medical implications of dendritic cell (DC) biology for disease prevention and therapy.
13. Disis ML, Cheever MA: HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol. 18, 37-45 (1998).
14. Disis ML, Gooley TA, Rinn K et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632 (2002).
15. Cibotti R, Kaneliopoulos JM, Cabaniols JP et al.: Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl Acad. Sci. USA 89, 416-420 (1992).
16. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A: Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J. Immunol. 167, 787-796 (2001).
17. Elliott T, Cerundolo V, Elvin J, Townsend A: Peptide-induced conformational change of the class I heavy chain. Nature 351, 402-406 (1991).
18. Sette A, Vitiello A, Reherman B et al.: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
19. Ward S, Casey D, Labarthe MC et al.: Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51, 351-357 (2002).
20. Finn OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
21. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
22. Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007). ■ Overview of tumor-induced immune escape mechanisms.
23. Drake CG, Jaffee E, Pardoll DM: Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006).
24. Gabrilovich D: Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
25. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E: Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate anti-tumor immunity. Blood 101, 245-252 (2003).
26. Feng H, Zeng Y, Whitesell L, Katsanis E: Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 97, 3505-3512 (2001).
27. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E: Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol. Immunother. 59(1), 1-11 (2009).
28. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ: Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother. 57, 1559-1568 (2008).
29. Tuyaerts S, Aerts JL, Corthals J et al.: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56, 1513-1537 (2007).
30. Inaba K, Inaba M, Romani N et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
31. Schreurs MW, Eggert AA, de Boer AJ, Figdor CG, Adema GJ: Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur. J. Immunol. 29, 2835-2841 (1999).
32. Romani N, Gruner S, Brang D et al.: Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
33. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF'TNF-α. J. Exp. Med. 184, 695-706 (1996).
34. + progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55, 1209-1218 (2006).
35. + progenitor-derived dendritic cells. J. Exp. Med. 199, 1503-1511 (2004).
36. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177-1182 (1997).
37. Fields RC, Shimizu K, Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95, 9482-9487 (1998).
38. Geiger C, Regn S, Weinzierl A, Noessner E, Schendel DJ: A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J. Transl. Med. 3, 29 (2005).
39. Phan V, Errington F, Cheong SC et al.: A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat. Med. 9, 1215-1219 (2003).
40. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434 (2000).
41. Wolfers J, Lozier A, Raposo G et al.: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297-303 (2001).
42. Ueda G, Tamura Y, Hirai I et al.: Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci. 95, 248-253 (2004).
43. Wang XH, Qin Y, Hu MH, Xie Y: Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 54, 971-980 (2005).
44. Andre F, Schartz NE, Movassagh M et al.: Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295-305 (2002).
45. Waldhauer I, Goehlsdorf D, Gieseke F et al.: Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68, 6368-6376 (2008).
46. Nencioni A, Grunebach F, Schmidt SM et al.: The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65, 191-199 (2008).
47. Grunebach F, Erndt S, Hantschel M, Heine A, Brossart P: Generation of antigen-specific CTL responses using RGSl mRNA transfected dendritic cells. Cancer Immunol. Immunother. 57, 1483-1491 (2008).
48. Yasuda T, Kamigaki T, Kawasaki K et al.: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 56(7), 1025-1036 (2006).
49. Kao JY, Zhang M, Chen CM, Chen JJ: Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett. 101, 154-159 (2005).
50. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51, 299-310 (2002).
51. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27, 265-272 (2004).
52. Ribas A: Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 5, 619-628 (2005).
53. Breckpot K, Heirman C, Neyns B, Thielemans K: Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J. Gene Med. 6, 1175-1188 (2004).
54. Todryk SM, Birchall LJ, Erlich R, Halanek N, Orleans-Lindsay JK, Dalgleish AG: Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology 102, 190-198 (2001).
55. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ: Dendritic cells: tools and targets for anti-tumor vaccination. Expert Rev. Vaccines 4, 699-710 (2005).
56. Adema GJ: Dendritic cells from bench to bedside and back. Immunol. Lett. 122, 128-130(2009).
57. den Brok MH, Sutmuller RP, Nierkens S et al.: Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 66, 7285-7292 (2006).
58. Hodge JW, Rad AN, Grosenbach DW et al.: Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl Cancer Inst. 92, 1228-1239 (2000).
59. MartIn-Fontecha A, Sebastiani S, Hopken UE et al.: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198, 615-621 (2003).
60. Nestle FO, Alijagic S, Gilliet M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
61. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS: Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107-116 (2003).
62. Chen M, Huang L, Shabier Z, Wang J: Regulation of the lifespan in dendritic cell subsets. Mol. Immunol. 44, 2558-2565 (2007).
63. Kim TW, Lee JH, He L et al.: Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65, 309-316 (2005).
64. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57, 1569-1577 (2008). ■ Overview of whole-tumor cell-based DC vaccination studies.
65. O'Rourke MG, Johnson M, Lanagan C et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52, 387-395 (2003).
66. Larmonier N, Merino D, Nicolas A et al.: Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 11, 1513-1524 (2006).
67. Melero I, Vile RG, Colombo MP: Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther. 7, 1167-1170 (2000).
68. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
69. Schnurr M, Scholz C, Rothenfusser S et al.: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells. Cancer Res. 62, 2347-2352 (2002).
70. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G: Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 12, 699-707 (2005).
71. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
72. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int. Immunol. 12, 1539-1546 (2000).
73. Nicolas A, Cathelin D, Larmonier N et al.: Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J. Immunol. 179, 812-818 (2007).
74. Kalos M: Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21, 781-786 (2003).
75. Zeng Y, Graner MW, Katsanis E: Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol. Immunother. 55, 329-338 (2006).
76. Gilboa E: The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. 2, 789-792 (2001).
77. Bos R, van Duikeren S, Morreau H et al.: Balancing between anti-tumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 68, 8446-8455 (2008).
78. Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H: Immunotherapy with dendritic cells for prostate cancer. Int. J. Cancer 121, 467-473 (2007).
79. Nencioni A, Muller MR, Grunebach F et al.: Dendritic cells transfected with tumor RNA for the induction of anti-tumor CTL in colorectal cancer. Cancer Gene Ther. 10, 209-214 (2003).
80. Muller MR, Grunebach F, Nencioni A, Brossart P: Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J. Immunol. 170, 5892-5896 (2003).
81. Holtl L, Zelle-Rieser C, Gander H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8, 3369-3376 (2002).
82. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A: Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87, 989-1001 (2002).
83. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306, 517-522 (1982).
84. Meeker T, Lowder J, Cleary ML et al.: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658-1665 (1985).
85. Houot R, Levy R: Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 23, 137-142 (2009). ■ Highlights clinical implications of idiotype-based vaccines for immunotherapy of B-cell lymphoma.
86. Timmerman JM, Czerwinski DK, Davis TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526 (2002).
87. Blachere NE, Srivastava PK: Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin. Cancer Biol. 6, 349-355 (1995).
88. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269, 1585-1588 (1995).
89. Asea A, Kraeft SK, Kurt-Jones EA et al.: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 435-442 (2000).
90. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E: Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin. Cancer Res. 6, 909-915 (2000).
91. Udono H, Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178, 1391-1396 (1993).
92. Udono H, Srivastava PK: Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol. 152, 5398-5403 (1994).
93. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV: Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J. Immunol. 162, 6426-6432 (1999).
94. Basu S, Srivastava PK: Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor-and peptide-specific immunity. J. Exp. Med. 189, 797-802 (1999).
95. Arnold D: Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182, 885-889 (1995).
96. Li Z, Qiao Y, Liu B et al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 11, 4460-4468 (2005).
97. Rivoltini L, Castelli C, Carrabba M et al.: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J. Immunol. 171, 3467-3474 (2003).
98. Belli F, Testori A, Rivoltini L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002)
99. (Erratum appears in J. Clin. Oncol. 20(23), 4610 [2002]). ■ Clinical and immunologic analysis of autologous heat shock protein-based vaccine trial in humans.
100. Udono H, Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178, 1391-1396 (1993).
101. Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV: Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J. Immunol. 162, 6426-6432 (1999).
102. Arnold D, Faath S, Rammensee H, Schild H: Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 182, 885-889 (1995).
103. Srivastava PK, Udono H: Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6, 728-732 (1994).
104. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL: Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8, 657-665 (1998).
105. Ishii T, Udono H, Yamano T et al.: Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol. 162, 1303-1309 (1999).
106. Zeng Y, Chen X, Larmonier N et al.: Natural killer cells play a key role in the anti-tumor immunity generated by chaperone-rich cell lysate vaccination. Int. J. Cancer 119, 2624-2631 (2006).
107. Graner M, Raymond A, Akporiaye E, Katsanis E: Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent anti-tumor vaccines. Cancer Immunol. Immunother. 49, 476-484 (2000).
108. Graner MW, Likhacheva A, Davis J et al.: Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res. 64, 8085-8092 (2004).
109. Graner MW, Zeng Y, Feng H, Katsanis E: Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 52, 226-234 (2003).
110. Zeng Y, Feng H, Graner MW, Katsanis E: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent anti-tumor immunity. Blood 101,4485-4491 (2003).
111. Rivoltini L, Carrabba M, Huber V et al.: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113 (2002).
112. Belli F, Testori A, Rivoltini L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20, 4169-4180 (2002).
113. + tumor cells. Blood 105, 2016-2022 (2005).
114. Li G, Zeng Y, Chen X et al.: Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin. Exp. Immunol. 148, 136-145 (2007).
115. Cantrell J, Larmonier C, Janikashvili N et al.: Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology DOI: 10.1016/j.imbio.2009.09.006 (Epub ahead of print) (2009).
116. Larmonier N, Cantrell J, Lacasse C et al.: Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J. Leukoc. Biol. 83, 1049-1059 (2008).
117. Li G, Andreansky S, Helguera G et al.: A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol. Cancer Ther. 7, 721-729 (2008).
118. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E: Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J. 21, 2173-2184 (2007).
119. De Vries IJ, Krooshoop DJ, Scharenborg NM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63, 12-17 (2003).
120. Cheng F, Wang HW, Cuenca A et al. : A critical role for Stat3 signaling in immune tolerance. Immunity 19, 425-436 (2003).
121. Ueno H, Klechevsky E, Morita R et al.: Dendritic cell subsets in health and disease. Immunol. Rev. 219, 118-142 (2007).
122. Bromberg JF, Wrzeszczynska MH, Devgan G et al.: Stat3 as an oncogene. Cell 98, 295-303 (1999).
123. Wang T, Niu G, Kortylewski M et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004).
124. Kortylewski M, Kujawski M, Wang T et al.: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent anti-tumor immunity. Nat. Med. 11, 1314-1321 (2005).
125. Burdelya L, Kujawski M, Niu G et al.: Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxidemediated anti-tumor effects. J. Immunol. 174,3925-3931 (2005).
126. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY: SOCS1 restricts dendritic cells' ability to break self tolerance and induce anti-tumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116, 90-100 (2006).
127. Melief CJ: Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33, 2645-2654 (2003).
128. Vermi W, Bonecchi R, Facchetti F et al.: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200, 255-268 (2003).
129. Salio M, Cella M, Vermi W et al.: Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33, 1052-1062 (2003).
130. Munn DH, Sharma MD, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004).
131. Zhang M, Tang H, Guo Z et al.: Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol. 5, 1124-1133 (2004).
132. + myeloid cells. J. Immunol. 166, 5398-5406 (2001).
133. + cells in the development of anti-tumor immunity. Cancer Res. 64, 1130-1139 (2004).
134. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-1131 (2006).
135. Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
136. + regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol. Immunother. 56, 48-59 (2007).
137. - tumors. J. Immunol. 181, 6955-6963 (2008). ■ Demonstrates the synergistic effects of tumor-lysate-pulsed DCs with regulatory T-cell suppression.
138. Yang YA, Dukhanina O, Tang B et al.: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615 (2002).
139. Muraoka RS, Dumont N, Ritter CA et al.: Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559 (2002).
140. UhI M, Aulwurm S, Wischhusen J et al.: SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64,7954-7961 (2004).
141. Dannull J, Su Z, Rizzieri O et al.: Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005).
142. Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA: Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother. 29, 208-214 (2006).
143. North RJ: Cydophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155, 1063-1074 (1982).
144. + regulatoryT cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344 (2004).
145. + murine leukemia. Int. J. Cancer 110, 251-259 (2004).